Biliary dyskinesia future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Biliary dyskinesia}} | {{Biliary dyskinesia}} | ||
{{CMG}} {{AE}} {{SHA}} | |||
== Overview == | == Overview == | ||
| Line 7: | Line 8: | ||
== Future or Investigational Therapies == | == Future or Investigational Therapies == | ||
* Further studies are required to assess the outcome of [[Surgery|surgical]] ([[cholecystectomy]]) versus nonsurgical [[Treatment|treatments]] (those used in treatment of other functional disorders) in bilary dyskinesia. | * Further studies are required to assess the outcome of [[Surgery|surgical]] ([[cholecystectomy]]) versus nonsurgical [[Treatment|treatments]] (those used in treatment of other functional disorders) in bilary dyskinesia.<ref name="pmid32266192">{{cite journal| author=Simon DA, Friesen CA, Schurman JV, Colombo JM| title=Biliary Dyskinesia in Children and Adolescents: A Mini Review. | journal=Front Pediatr | year= 2020 | volume= 8 | issue= | pages= 122 | pmid=32266192 | doi=10.3389/fped.2020.00122 | pmc=7105807 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32266192 }} </ref> | ||
* Some of the medical treatments that have been effective in other functional disorders include treatments for: | * Some of the medical treatments that have been effective in other functional disorders include treatments for:<ref name="pmid32266192">{{cite journal| author=Simon DA, Friesen CA, Schurman JV, Colombo JM| title=Biliary Dyskinesia in Children and Adolescents: A Mini Review. | journal=Front Pediatr | year= 2020 | volume= 8 | issue= | pages= 122 | pmid=32266192 | doi=10.3389/fped.2020.00122 | pmc=7105807 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32266192 }} </ref> | ||
** Dysmotility (such as [[Cisapride (patient information)|cisapride]] or [[erythromycin]]) | ** Dysmotility (such as [[Cisapride (patient information)|cisapride]] or [[erythromycin]]) | ||
** [[Hyperalgesia]] (such as [[antidepressants]]) | ** [[Hyperalgesia]] (such as [[antidepressants]]) | ||
Revision as of 08:48, 16 August 2020
|
Biliary dyskinesia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Biliary dyskinesia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Biliary dyskinesia future or investigational therapies |
|
FDA on Biliary dyskinesia future or investigational therapies |
|
CDC on Biliary dyskinesia future or investigational therapies |
|
Biliary dyskinesia future or investigational therapies in the news |
|
Blogs on Biliary dyskinesia future or investigational therapies |
|
Risk calculators and risk factors for Biliary dyskinesia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
Further studies are required to assess the outcome of surgical (cholecystectomy) versus nonsurgical treatments (those used in treatment of other functional disorders) in bilary dyskinesia.
Future or Investigational Therapies
- Further studies are required to assess the outcome of surgical (cholecystectomy) versus nonsurgical treatments (those used in treatment of other functional disorders) in bilary dyskinesia.[1]
- Some of the medical treatments that have been effective in other functional disorders include treatments for:[1]
- Dysmotility (such as cisapride or erythromycin)
- Hyperalgesia (such as antidepressants)
- Inflammation (such as mast cell stabilizers)
- Psychosocial therapy (such as cognitive-behavioral therapy)